Safety and immunogenicity of MAGE-A3 cancer immunotherapeutic with dacarbazine in patients with MAGE-A3-positive metastatic cutaneous melanoma: an open phase I/II study with a first assessment of a predictive gene signature.
about
Safety and immunogenicity of MAGE-A3 cancer immunotherapeutic with dacarbazine in patients with MAGE-A3-positive metastatic cutaneous melanoma: an open phase I/II study with a first assessment of a predictive gene signature.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Safety and immunogenicity of M ...... f a predictive gene signature.
@en
Safety and immunogenicity of M ...... f a predictive gene signature.
@nl
type
label
Safety and immunogenicity of M ...... f a predictive gene signature.
@en
Safety and immunogenicity of M ...... f a predictive gene signature.
@nl
prefLabel
Safety and immunogenicity of M ...... f a predictive gene signature.
@en
Safety and immunogenicity of M ...... f a predictive gene signature.
@nl
P2093
P2860
P1433
P1476
Safety and immunogenicity of M ...... of a predictive gene signature
@en
P2093
Anne Dompmartin
Brigitte Dréno
Caroline Robert
Céleste Lebbe
Florent Grange
Frédéric F Lehmann
Jamila Louahed
Jean Francois Baurain
Jean-Jacques Grob
Lionel D'Hondt
P2860
P304
P356
10.1136/ESMOOPEN-2017-000203
P577
2017-11-14T00:00:00Z